Introduction
Wales is a small nation (population 3.1 million in 2014) and shares a land border with England (population 54.3 million in 2014) with which it forms part of the United Kingdom (population 64.6 million in 2014). 1 Centre.
The tricyclic antidepressant dosulepin has been found to have an increased risk of toxicity in overdose compared to other tricyclic antidepressants with the possible exception of doxepin. Whilst randomised controlled trials (RCTs) represent the standard approach for assessing the outcome of many interventions, the methodology employed in these studies cannot be easily used to evaluate population level changes. The utility of natural experiments to overcome some of the limitations of RCTs in this regard has been recognised by the Medical Research Council. 8 In these studies data has typically been collected pre and post intervention, and the change over time analysed using interrupted time series analysis such as autoregressive integrated moving average (ARIMA) models. 9 Dosulepin prescribing in both Wales and England may have been influenced by the MHRA and NICE CG90 advice. However, only usage in Wales has been subject to monitoring by a prescribing indicator. The publication of this prescribing advice and the regional differences between these potential influences on dosulepin usage formed the basis of a natural experiment to assess changes in GP prescribing behaviour in Wales and NE England.
The purpose of this study was to examine trends in dosulepin usage in Wales and NE England (an area with comparable demographic and socioeconomic characteristics to Wales 10 ) prior to and following publication of the MHRA safety warning, NICE CG90 and the introduction of the AWMSG NPI. The rate of change in primary care dosulepin usage in the 12 months prior to and following the introduction of each intervention was analysed using an ARIMA model.
Methods

Data source
Monthly 
Results
Insert Figure 1 here
The prescribing of dosulepin in Wales and NE England during the period of study is shown in figure 1 .
MHRA advice
Insert Figure 2 here In NE England, the rate of change in dosulepin use was -0.37 DDDs/1,000 PUs per month prior to publication of the NICE guideline, and -0.34 DDDs/1,000 PUs per month in the 12 months after September 2009. These rates of change were not significantly different (p=0.87).
AWMSG NPI
Insert Figure 4 here 
Discussion
There were no statistically significant differences between the rates of change in dosulepin rather than a gradual effect over time.
It must also be noted that the data obtained from CASPA and ePACT used in this study gave a measure of prescriptions dispensed and submitted for pricing and did not necessarily directly correlate with prescribing in primary care. Therefore, prescriptions issued to patients but not subsequently taken to a pharmacy for dispensing would not be identified. The potential significance of this confounder was likely to be limited, as the number of dosulepin items dispensed each month and recorded on CASPA was relatively high (12,038 in Wales in March 2011) and it would be anticipated that the number of any non-dispensed prescriptions was small. This may have been particularly true in Wales due to the absence of a prescription charge. If patients had received a prescription from a GP, they would have been less likely not to have it dispensed for financial reasons than in England, where prescription charges apply.
The MHRA safety warning and NICE CG90 were available to GPs in Wales and NE England and both therefore had the potential to influence dosulepin usage in each of the two regions.
The absence of a change in the rate of usage following the publication of prescribing advice was a concern in light of the risk of toxicity associated with this antidepressant in overdose. previously been reported. [13] [14] [15] Changes in rosiglitazone and pioglitazone prescribing in the Netherlands appeared to be associated with the publication of safety warnings. 13 In the Republic of Ireland, a warning of increased cardiac risk associated with celecoxib resulted in a significant change in prescribing behaviour, whereas warnings for clopidogrel, co-amoxiclav and haloperidol had little or no effect. 14 A number of factors, including lack of awareness of, and agreement with guidelines have been cited as barriers to change in prescribing behaviour. 11, 16 Pharmacist involvement has been suggested as a method to overcome some of the barriers to change 17 and may have provided a mechanism through which the aim of the NPI was translated into practice. Primary care pharmacists working with GP practices in a number of the health boards in Wales have conducted work to reduce dosulepin usage in response to the NPI. Engagement and collaboration between policy makers, primary care pharmacists and practices may help to maximise changes in prescribing behaviour.
Conclusions
The trend in dosulepin usage in Wales altered significantly following the introduction of the AWMSG NPI. The relationship between the timing of this change and the introduction of the NPI coupled with the absence of a significant change in the rate of usage in NE England over the same period provided evidence that the NPI may have prompted a change in prescribing behaviour. Despite the gradual decline in dosulepin usage seen in both of the geographical areas over time, the aim of introducing the NPI was to improve patient safety. Linking the observed change in prescribing to changes in patient outcomes is the subject of further work.
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